Guggenheim keeps Buy ratings on Elevance Health and Everpure

what happened

TradingView, citing a Guggenheim analyst note, reported that the bank maintained its Buy rating on Elevance Health and a $460.00 price target. The target represents implied upside of 11.5% from the stock’s Oct. 9 close of $412.70.

Analysts highlighted resilience and improvement across Elevance Health’s Medicaid, Medicare Advantage and ACA businesses. Management indicated that these areas are performing better than initially expected, which is seen as supporting earnings growth and creating a largely de-risked setup for 2026. A diversified earnings base and cost-control measures also support a recovery, including targeted adjusted EPS growth of more than 12% by 2027.

Guggenheim also maintained a Buy rating on Everpure, with a $215.00 target. The target implies 39.2% upside from the Oct. 9 close of $154.49. Everpure has gained market share in both rising and falling NAND-price environments, while revenue growth is expected to come from hyperscaler customers and the data primacy trend. The note also says Guggenheim raised its price target; Everpure projects 39–45% growth and 24–26% operating margins in FY28.

why it matters

The two ratings reflect Guggenheim’s constructive view of earnings and margin prospects. The TradingView report, which includes selected reference data from Benzinga, is not personal investment advice.

instruments